New Drug Trial for Bladder Cancer Patients
New Drug Trial for Bladder Cancer Patients
Researchers have called this new drug a ray of hope for patients suffering from bladder cancer, particularly for those who do not respond to standard treatments.
The drug, named Crestostemogen Grenadineripevic, has shown remarkable results, eliminating the disease in three-quarters of cancer patients involved in the trial. These were patients who had not found relief from immune-related treatments.
Dr. Mark Tyson, a urologic oncologist and the lead researcher at the Mayo Clinic Comprehensive Cancer Center in Rochester, Minnesota, stated that the study results offer a new treatment option for bladder cancer patients, something that has never been seen before. This treatment could significantly improve their quality of life.
The findings were presented on Thursday at the Annual Meeting of the Society of Urologic Oncology in Dallas.
According to the American Cancer Society, over 83,000 new cases of bladder cancer are diagnosed annually in the United States, with approximately 17,000 deaths each year. The disease primarily affects older individuals, and it is more commonly diagnosed in men than in women.
Comments
Post a Comment